Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181

J Antimicrob Chemother. 2011 Jan;66(1):15-28. doi: 10.1093/jac/dkq387. Epub 2010 Nov 21.

Abstract

Background: influenza viruses (IFVs) frequently achieve resistance to antiviral drugs, necessitating the development of compounds with novel mechanisms of action. DAS181 (Fludase), a sialidase fusion protein, may have a reduced potential for generating drug resistance due to its novel host-targeting mechanism of action.

Methods: IFV strains B/Maryland/1/59 and A/Victoria/3/75 (H3N2) were subjected to >30 passages under increasing selective pressure with DAS181. The DAS181-selected IFV isolates were characterized in vitro and in mice.

Results: despite extensive passaging, DAS181-selected viruses exhibited a very low level of resistance to DAS181, which ranged between 3- and 18-fold increase in EC(50). DAS181-selected viruses displayed an attenuated phenotype in vitro, as exhibited by slower growth, smaller plaque size and increased particle to pfu ratios relative to wild-type virus. Further, the DAS181 resistance phenotype was unstable and was substantially reversed over time upon DAS181 withdrawal. In mice, the DAS181-selected viruses exhibited no greater virulence than their wild-type counterparts. Genotypic and phenotypic analysis of DAS181-selected viruses revealed mutations in the haemagglutinin (HA) and neuraminidase (NA) molecules and also changes in HA and NA function.

Conclusions: results indicate that resistance to DAS181 is minimal and unstable. The DAS181-selected IFV isolates exhibit reduced fitness in vitro, likely due to altered HA and NA functions.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antiviral Agents / pharmacology*
  • Drug Resistance, Viral*
  • Female
  • Genotype
  • Humans
  • Influenza A virus / drug effects*
  • Influenza A virus / genetics
  • Influenza A virus / growth & development
  • Influenza A virus / pathogenicity
  • Influenza B virus / drug effects*
  • Influenza B virus / genetics
  • Influenza B virus / growth & development
  • Influenza B virus / pathogenicity
  • Mice
  • Mice, Inbred BALB C
  • Mutation*
  • Orthomyxoviridae Infections / pathology
  • Orthomyxoviridae Infections / virology
  • Phenotype
  • Recombinant Fusion Proteins / pharmacology*
  • Selection, Genetic*
  • Serial Passage
  • Viral Plaque Assay
  • Virulence
  • Virus Replication

Substances

  • Antiviral Agents
  • Recombinant Fusion Proteins
  • oplunofusp